Adverse effects of anticancer agents that target the VEGF pathway

Chen, Helen X.; Cleck, Jessica N.

doi:10.1038/nrclinonc.2009.94

Cited by 560Angiogenesis and VEGF in CancerChemotherapy-related skin toxicityLymphatic System and Diseases

Adverse effects of anticancer agents that target the VEGF pathway

Chen, Helen X., Cleck, Jessica N.·2009·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2009.94

Open this paper in CoChat — free account

Abstract

Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an important part of standard therapy in multiple cancer indications. With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair. Although most adverse effects of VEGF inhibitors are modest and manageable, some are associated with serious and life-threatening consequences, particularly in high-risk patients and in certain clinical settings. This Review examines the toxicity profiles of anti-VEGF antibodies and small-molecule inhibitors. The potential mechanisms of the adverse effects, risk factors, and the implications for selection of patients and management are discussed.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2009.94

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In HARBOR, monthly ranibizumab was linked to more geographic atrophy than PRN (HR, 1.3; 95% CI, 1.0-1.7).
“In the HARBOR trial, eyes that received monthly ranibizumab had a higher incidence of geographic atrophy when compared with PRN treatment (HR, 1.3; 95% CI, 1.0–1.7).29”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [29]

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386 · see citing works
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · see citing works
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752 · see citing works
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,606 · see citing works
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802 · see citing works
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,019 · see citing works
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,077 · see citing works
Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · see citing works
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
Yang, J. C., Haworth, L. R., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,681 · see citing works
Self-citation
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G. A., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,646 · see citing works
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Escudier, B. J., Pluzanska, A., Koralewski, P., Ravaud, A., Sergio Bracarda, A., Szczylik, C. A., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,216 · see citing works
Problem based learning
Wood, D. F. (2003) · BMJ · doi:10.1136/bmj.326.7384.328 · Cited by 2,140 · see citing works
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Höchster, H. S., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504 · see citing works
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases
Eremina, V., Sood, M. M., Haigh, J. J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H. P., Kikkawa, Y., Miner, J. H., & Quaggin, S. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17423 · Cited by 1,308 · see citing works
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M., Marcom, P. K., Fehrenbacher, L., Dickler, M. N., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,303 · see citing works
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
Faivre, S. J., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C. L., DePrimo, S. E., Brega, N. M., Massimini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,162 · see citing works
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkelä, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L. L. H., Woulfe, K. C., Pravda, E. A., Cassiola, F. M., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,081 · see citing works
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H. P., Miller, K. D., Kabbinavar, F. F., Bergsland, E. K., Ngai, J., Holmgren, E. B., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 934 · see citing works
Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 883 · see citing works
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O’Brien, S., Davis, R. B., Gowen, L. C., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 776 · see citing works
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
Nalluri, S. R., Chu, D. T. W., Keresztes, R. S., Zhu, X., & Wu, S. (2008) · JAMA · doi:10.1001/jama.2008.656 · Cited by 765 · see citing works
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H. M., Douglas, J., Burger, R. A., Armstrong, D. K., Wenham, R. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 760 · see citing works
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 720 · see citing works
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
Gerber, H., Malik, A. K., Solar, G. P., Sherman, D. A., Liang, X. H., Meng, G., Hong, K., Marsters, J. C., & Ferrara, N. (2002) · Nature · doi:10.1038/nature00821 · Cited by 706 · see citing works
VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
Hood, J. D., Meininger, C. J., Ziche, M., & Granger, H. J. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.3.h1054 · Cited by 696 · see citing works
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications
Ferrara, N. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70064-x · Cited by 692 · see citing works
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Grothey, A. F., Sugrue, M. M., Purdie, D. M., Dong, W., Sargent, D. J., Hedrick, E. E., & Kozloff, M. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3212 · Cited by 688 · see citing works
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Hu‐Lowe, D. D., Zou, H. Y., Grazzini, M. L., Hallin, M. E., Wickman, G., Amundson, K., Chen, J. H., Rewolinski, D. A., Yamazaki, S., Wu, X., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0652 · Cited by 640 · see citing works
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
Schneider, B. P., Wang, Μ., Radovich, M., Sledge, G. W., Badve, S., Thor, A. D., Flockhart, D. A., Hancock, B. A., Davidson, N. E., Gralow, J. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604 · see citing works
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications
Ferrara, N. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37264 · Cited by 552 · see citing works
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
García, A. A., Hirte, H. W., Fleming, G. F., Yang, D., Tsao-Wei, D. D., Roman, L. D., Groshen, S. G., Swenson, S. D., Markland, F. S., Gandara, D. R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547 · see citing works
Self-citation
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
Scappaticci, F. A., Fehrenbacher, L., Cartwright, T. H., Hainsworth, J. D., Heim, W. J., Berlin, J. D., Kabbinavar, F. F., Novotny, W. F., Sarkar, S., & Hurwitz, H. I. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20301 · Cited by 535 · see citing works
Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer
Wedam, S. B., Low, J. A., Yang, S. X., Chow, C. K., Choyke, P. L., Danforth, D. N., Hewitt, S. M., Berman, A. W., Steinberg, S. M., Liewehr, D. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4645 · Cited by 516 · see citing works
Self-citation
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology
Schrijvers, B. F., Flyvbjerg, A., & Vriese, A. S. D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00621.x · Cited by 504 · see citing works
Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma
Goodman, V. L., Rock, E. P., Dagher, R. N., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 502 · see citing works
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., Okumura, S., Nakagawa, K., Soda, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815e8b60 · Cited by 466 · see citing works
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Rixe, O., Bukowski, R. M., Michaelson, M. D., Wilding, G., Hudes, G. R., Bolte, O., Motzer, R. J., Bycott, P. W., Liau, K., Freddo, J. L., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70285-1 · Cited by 435 · see citing works
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., Morgan, J. A., Dychter, S. S., Larsen, P. R., Demetri, G. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00008 · Cited by 402 · see citing works
Neuroimaging in Posterior Reversible Encephalopathy Syndrome
Lamy, C., Oppenheim, C., Méder, J.-F., & Mas, J. (2004) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2004.tb00223.x · Cited by 374 · see citing works
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function
Giordano, F. J., Gerber, H., Williams, S., van Bruggen, N., Bunting, S., Ruiz‐Lozano, P., Gu, Y., Nath, A. K., Huang, Y., Hickey, R. P., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091415198 · Cited by 370 · see citing works
Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab
Glusker, P., Recht, L. D., & Lane, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmc052954 · Cited by 364 · see citing works
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Lü, J., Bruno, R., Eppler, S., Novotny, W. F., Lum, B. L., & Gaudreault, J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0664-8 · Cited by 352 · see citing works
Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
Ramalingam, S. S., Dahlberg, S. E., Langer, C. J., Gray, R. J., Belani, C. P., Brahmer, J. R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1144 · Cited by 348 · see citing works
Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L. M., Sarosy, G., Kotz, H. L., Premkumar, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8332 · Cited by 331 · see citing works
Self-citation
Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation.
Katoh, O., Tauchi, H., Kawaishi, K., et al. (1995) · PubMed · Cited by 305 · see citing works
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
Drevs, J., Siegert, P., Medinger, M., Mross, K. B., Strecker, R., Zirrgiebel, U., Harder, J., Blum, H. E., Robertson, J. D., Jürgensmeier, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2066 · Cited by 303 · see citing works
Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed
Stott, V. L., Hurrell, M., & Anderson, T. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2004.00750.x · Cited by 296 · see citing works
A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans
Eppler, S. M., Combs, D. L., Henry, T. D., López, J. J., Ellis, S. G., Yi, J., Annex, B. H., McCluskey, E. R., & Zioncheck, T. F. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126179 · Cited by 267 · see citing works
Vascular Endothelial Growth Factor/Vascular Permeability Factor Produces Nitric Oxide–Dependent Hypotension
Horowitz, J. R., Rivard, A., van der Zee, R., Hariawala, M. D., Sheriff, D. D., Esakof, D. D., Chaudhry, G. M., Symes, J. F., & Isner, J. M. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.11.2793 · Cited by 266 · see citing works
Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer
Allegra, C. J., Yothers, G., O’Connell, M. J., Sharif, S., Colangelo, L. H., Lopa, S., Petrelli, N. J., Goldberg, R. M., Atkins, J. N., Seay, T. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9220 · Cited by 260 · see citing works
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
D’Adamo, D. R., Anderson, S. E., Albritton, K. H., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., & Maki, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.139 · Cited by 252 · see citing works
Self-citation
Heart failure associated with sunitinib malate
Khakoo, A. Y., Kassiotis, C., Tannir, N. M., Plana, J. C., Halushka, M. K., Bickford, C. L., Trent, J., Champion, J. C., Durand, J., & Lenihan, D. J. (2008) · Cancer · doi:10.1002/cncr.23460 · Cited by 251 · see citing works
Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group
McDermott, D. F., Sosman, J. A., Gonzalez, R. C., Hodi, F. S., Linette, G. P., Richards, J. M., Jakub, J. W., Beeram, M., Tarantolo, S., Agarwala, S. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8288 · Cited by 250 · see citing works
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
Spano, J., Chodkiewicz, C., Maurel, J., Wong, R., Wasan, H. S., Barone, C., Letourneau, R., Bajetta, E., Pithavala, Y. K., Bycott, P. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60661-3 · Cited by 250 · see citing works
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.
Miles, D., Chan, A., Romieu, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba1011 · Cited by 214 · see citing works
Thrombospondin‐1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice
Streit, M., Velasco, P., Riccardi, L., Spencer, L., Brown, L. F., Janes, L., Lange‐Asschenfeldt, B., Yano, K., Hawighorst, T., Iruela‐Arispe, L., et al. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3272 · Cited by 207 · see citing works
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
Furuse, J., Ishii, H., Nakachi, K., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00648.x · Cited by 196 · see citing works
Angiogenic growth factors and hypertension
Sane, D. C., Anton, L., & Brosnihan, K. B. (2004) · Angiogenesis · doi:10.1007/s10456-004-2699-3 · Cited by 195 · see citing works
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib
Bollée, G., Patey, N., Cazajous, G., Robert, C., Goujon, J. M., Fakhouri, F., Bruneval, P., Noël, L., & Knebelmann, B. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn657 · Cited by 184 · see citing works
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias
Karp, J. E., Gojo, I., Пили, Р., Gocke, C. D., Greer, J. M., Guo, C., Qian, D. Z., Morris, L. E., Tidwell, M., Chen, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0627 · Cited by 180 · see citing works
Self-citation
Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704
Manegold, C., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V. A., Hirsch, V., Leighl, N. B., Mezger, J., Archer, V. R., & Reck, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.lba7514 · Cited by 168 · see citing works
Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma
Frangié, C., Lefaucheur, C., Médioni, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70037-2 · Cited by 158 · see citing works
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
Azad, N. S., Aragon‐Ching, J. B., Dahut, W. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1141 · Cited by 145 · see citing works
Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer
Allen, J. A., Adlakha, A., & Bergethon, P. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1475 · Cited by 141 · see citing works
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
Kapiteijn, E., Brand, A., Kroep, J. R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm454 · Cited by 132 · see citing works
Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma
Wright, J. D., Hagemann, A. R., Rader, J. S., et al. (2006) · Cancer · doi:10.1002/cncr.21969 · Cited by 128 · see citing works
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
Minami, H., Kawada, K., Ebi, H., Kitagawa, K., Kim, Y., Araki, K., Mukai, H., Tahara, M., Nakajima, H., & Nakajima, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00837.x · Cited by 119 · see citing works
Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006
Govindarajan, R., Adusumilli, J., Baxter, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.4608 · Cited by 106 · see citing works
Reversible Posterior Leukoencephalopathy Syndrome Induced by Sunitinib
Martin, G., Bellido, L. M., & Cruz, J. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.8710 · Cited by 102 · see citing works
Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial
Socinski, M. A., Novello, S., Sanchez, J. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7001 · Cited by 101 · see citing works
Hypertension, Proteinuria, and Antagonism of Vascular Endothelial Growth Factor Signaling: Clinical Toxicity, Therapeutic Target, or Novel Biomarker?
van Heeckeren, W. J., Ortiz, J., Cooney, M. M., & Remick, S. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5113 · Cited by 100 · see citing works
Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma
Roncone, D., Satoskar, A. A., Nádasdy, T., et al. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0476 · Cited by 89 · see citing works
Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor
Hutson, T. E., Davis, I. D., Machiels, J. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5046 · Cited by 83 · see citing works
Thrombotic microangiopathy and anti-VEGF agents
Izzedine, H., Brochériou, I., Deray, G., et al. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl565 · Cited by 81 · see citing works
Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
Merchan, J. R., Liu, G., Fitch, T. R., Picus, J., Qin, R., Pitot, H. C., Maples, W. J., & Erlichman, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5034 · Cited by 80 · see citing works
Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma
Agarwala, S. S., Keilholz, U., Hogg, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8510 · Cited by 70 · see citing works
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Choueiri, T. K. (2008) · PubMed · Cited by 66 · see citing works
Hypertension-induced changes of platelet-derived growth factor receptor expression in rat aorta and heart.
Sarzani, R., Arnaldi, G., & Chobanian, A. V. (1991) · Hypertension · doi:10.1161/01.hyp.17.6.888 · Cited by 64 · see citing works
Reversible Posterior Leukoencephalopathy Syndrome Associated With Oxaliplatin
Pinedo, D., Shah-Khan, F. M., & Shah, P. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5954 · Cited by 53 · see citing works
Capillary rarefaction and abnormal cardiovascular reactivity in hypertension
Ciuffetti, G., Schillaci, G., Innocente, S., Lombardini, R., Pasqualini, L., Notaristefano, S., & Mannarino, E. (2003) · Journal of Hypertension · doi:10.1097/00004872-200312000-00018 · Cited by 47 · see citing works
A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results
Freyer, G., Fumoleau, P., You, B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.14539 · Cited by 44 · see citing works
Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma
Feldman, D. R., Ginsberg, M. S., Baum, M. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5100 · Cited by 42 · see citing works
Bevacizumab in the treatment of ovarian cancer
Han, E. S., & Monk, B. J. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.10.1339 · Cited by 41 · see citing works
Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104)
Miller, K. D., O’Neill, A., Perez, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.520 · Cited by 39 · see citing works
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
Sridhar, S. S., MacKenzie, M. J., Hotte, S. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5047 · Cited by 33 · see citing works
Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors
Zafar, S. Y., Bendell, J. C., Lager, J. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3097 · Cited by 33 · see citing works
Interstitial Nephritis Secondary to Bevacizumab Treatment in Metastatic Leiomyosarcoma
Barakat, R. K., Singh, N., Lal, R., et al. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h635 · Cited by 32 · see citing works
Growth-promoting effect of platelet-derived growth factor on rat cardiac myocytes
Liu, J., Wu, L., Li, L., et al. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.10.018 · Cited by 22 · see citing works
Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non–Small-Cell Lung Cancer
Wakelee, H. A., Kernstine, K. H., Vokes, E. E., Schiller, J. H., Baas, P., Saijo, N., Adjei, A. A., Goss, G. D., Gaspar, L. E., Gandara, D. R., et al. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.n.050 · Cited by 20 · see citing works
Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation
Levey, S. A., Bajwa, R., Picken, M. M., et al. (2008) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfn013 · Cited by 16 · see citing works
VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function
Steeghs, N., Hovens, M. M. C., Rabelink, T. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3037 · Cited by 13 · see citing works
Unlocking the Biological Clues of Lung Cancer
Hanna, N. H. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318183b0b7 · Cited by 9 · see citing works
Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event
Roncalli, J. G., Delord, J., Galinier, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl025 · Cited by 8 · see citing works
Final results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC).
Puzanov, I. J., Flaherty, K. T., Atkins, M. B., et al. (2007) · Molecular Cancer Therapeutics · Cited by 3 · see citing works

Flagged first, then by citations

Sorted by citations

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715 · see citing works
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708 · see citing works
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625 · see citing works
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration
Busbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500 · see citing works
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337 · see citing works
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331 · see citing works
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
Lancaster, L., Crestani, B., Hernandez, P., Inoue, Y., Wachtlin, D., Loaiza, L., Quaresma, M., Stowasser, S., & Richeldi, L. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000397 · Cited by 209 · see citing works
Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption
Kim, C., Yang, H., Fukushima, Y., Saw, P. E., Lee, J., Park, J.-S., Park, I., Jung, J., Kataoka, H., Lee, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.010 · Cited by 131 · see citing works
G‐CSF rescues tumor growth and neo‐angiogenesis during liver metastasis under host angiopoietin‐2 deficiency
Im, J. H., Tapmeier, T., Balathasan, L., Gal, A., Yameen, S., Hill, S., Smart, S., Noterdaeme, O., Kelly, M., Brady, M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27677 · Cited by 25 · see citing works
Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives
Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E. (2024) · Cancers · doi:10.3390/cancers16050890 · Cited by 11 · see citing works

Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases
Takeshi, Nishimura, Makoto, M., et al. (2011) · Acta Scientiarum Naturalium Universitatis Sunyatseni
Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes
Mahfoud, T., Tanz, R., Mesmoudi, M., et al. (2011) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-010-9245-x · Cited by 5 · see citing works
Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer
Mahfoud, T., & Réda, K. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu165.178
Two Cases of Leg Ulcer Caused by Bevacizumab
Jinnai, S., SUENAGA, A., Murata, M., et al. (2017) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.79.468 · Cited by 1 · see citing works
Two Cases of Emergency Operations in Patients Undergoing Bevacizumab Treatment
Yoshikawa, K., Shimada, M., Kurita, N., et al. (2010) · Nihon Daicho Komonbyo Gakkai Zasshi · doi:10.3862/jcoloproctology.63.56 · Cited by 3 · see citing works

Authors: Chen, H. X., & Cleck, J. N.
Affiliations: National Institutes of Health (US)
ORCID: Chen, Helen X.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2009-07-07
Volume: 6
Issue: 8
Pages: 465-477
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2009.94
OpenAlex: W1975058097
Cited by: 560
References: 97
Citations by year: 2026: 15 · 2025: 19 · 2024: 36 · 2023: 33 · 2022: 23 · 2021: 33 · 2020: 24 · 2019: 38 · 2018: 34 · 2017: 30 · 2016: 33 · 2015: 26 · 2014: 50 · 2013: 44 · 2012: 50
FWCI: 2.96
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords: VEGF inhibitors, anti-angiogenic therapy, adverse effects, drug toxicity, anti-VEGF antibody, cardiotoxicity, nephrotoxicity, wound healing, tissue repair, risk factors, patient selection, adverse effects management
MeSH terms: Bevacizumab, Sorafenib, Sunitinib, Antibodies, Monoclonal, Antineoplastic Agents, Benzenesulfonates, Brain Diseases, Cardiovascular Diseases, Clinical Trials as Topic, Drug Interactions, Forecasting, Gastrointestinal Diseases, Hemorrhage, Humans, Indoles, Kidney Diseases, Neoplasm Proteins, Niacinamide, Phenylurea Compounds, Pyridines, Pyrroles, Risk Factors, Wound Healing, Drug Delivery Systems, Capillary Leak Syndrome, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Protein Kinase Inhibitors, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adverse effects of anticancer agents that target the VEGF pathway

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks